Pfizer COVID-19 oral drug Paxlovid: One Phase II/III clinical trial failed
- Aspirin: Study Finds Greater Benefits for These Colorectal Cancer Patients
- Cancer Can Occur Without Genetic Mutations?
- Statins Lower Blood Lipids: How Long is a Course?
- Warning: Smartwatch Blood Sugar Measurement Deemed Dangerous
- Mifepristone: A Safe and Effective Abortion Option Amidst Controversy
- Asbestos Detected in Buildings Damaged in Ukraine: Analyzed by Japanese Company
Pfizer COVID-19 oral drug Paxlovid: One Phase II/III clinical trial failed
- Red Yeast Rice Scare Grips Japan: Over 114 Hospitalized and 5 Deaths
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Pfizer COVID-19 oral drug Paxlovid: One Phase II/III clinical trial failed.
On June 15, Pfizer announced a Phase II/III clinical (EPIC-SR) study of the COVID-19 oral drug Paxlovid in unvaccinated adults and vaccinated adults with one or more risk factors for progression to severe disease result.
However, the primary endpoint of sustained relief of all symptoms for 4 consecutive days was not met, and the secondary endpoint was not statistically significant.
Specifically, results of an interim analysis previously reported in December 2021 showed that the primary endpoint of sustained 4-day remission of COVID-19 symptoms was not met, and the key secondary endpoint was a 70% reduction in the relative risk of hospitalization or death (treatment arm: 3/428; Placebo: 10/426), not statistically significant.
Results of the latest analysis of 1,153 patients enrolled as of December 2021 showed a 51% relative risk reduction in hospitalization or death (treatment group: 5/576; placebo: 10/569), which was not statistically significant; for 721 patients A subgroup analysis of vaccinated adults with at least one risk factor for progression to severe COVID-19 showed a 57% reduction in the relative risk of hospitalization or death (treatment group: 3/361; placebo: 7/360).
Reference source:
Medical Rubik’s Cube info
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
